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Abstract 
Background: Helicobacter pylori (H. pylori) infection is a major cause 
of chronic gastritis, especially in metabolic syndrome patients. The use 
of a accessible and easy diagnostic method, can speed up the treatment 
of this infection This study compared two methods of histology and 
serology for diagnosis of H. pylori in metabolic syndrome patients. 
Methods: This study was done on 175 metabolic syndrome patients 
with dyspepsia referred to Shahroud Imam Hossain hospital in 2014. 
From each patient, standard biopsy and serology tests were taken with 
endoscopy. This data will be analyzed with sensitivity, specificity, 
positive and negative predictive value. 
Results: Of the 175 patients studied, 90 (51.4%) were male and 85 
(48.6%) were female. The mean patient age was 46.9±18.6 years. From 
175 patients, 114(65.1%)  and 149 (85.3%) patients tested positive by 
serology and histology, respectively. For the serological test, 
sensitivity, specificity, positive predictive value and negative predictive 
value were 66.4%, 42.3%, 86.8%, and 18.1%. It was also found that 
with IgG values higher than 1.3, there was a sensitivity of 90.7%, and 
specificity of 72.8%, which was considered a positive test. The cut-off 
point performance test means that  maximum at this point with 78.3% 
the area under the curve (AUC),  there is the highest sensitivity and 
specificity. 
Conclusions: Due to the relative sensitivity and specificity of 
serological tests in comparison with other diagnostic methods as well 
as the simplicity, speed, and low cost, it is recommended that this test 
be used for screening metabolic syndrome patients. 
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Introduction 
Helicobacter pylori (H. pylori), a gram negative, spiral, 
microaerophilic, is primarily located in the human gastric 
mucosa.1 This bacterium is the main cause of chronic gastritis 
and peptic ulcers, and it is considered the major risk factor for 
adenocarcinoma and gastric lymphoma.1-2 In 1994, it was 
classified as carcinogenic by the World Health Organization 
(Class I confirmed human carcinogen).1 Dyspepsia is a 
common finding in these patients and may be due to gastric 
inflation. About 30–50 percent of human populations are 
infected by this stomach bacterium in countries with higher 
levels of socioeconomic status, but in developing countries this 
percentage rises to 80 percent.2 In developing countries, such as 
Iran, 70% are infected at the age 10, and the infection rate 
increases with age. H. pylori infection is diagnosed on the basis 
of clinical and laboratory findings, microbiological methods, 
and histopathological examinations.3 Invasive methods of 
diagnosis can be divided into two categories: direct and  
indirect. Invasive procedures, such as endoscopy, are prepared 
by culture of biopsy specimens, staining of samples, and 
identification of urease activity.4 Although endoscopic 
examination is invasive, expensive, and time consuming, it is 
of critical importance in determining clinical prognosis on the 
basis of the localization of a lesion is. Histological diagnosis is 
frequently used to determine tissue inflammation and severity 
of precancerous alterations.5 These tests determine the presence 
or absence of anti-H.pylori antibodies in the serum of samples. 
Most patients with H.pylori infection have a significant amount 
of antibodies in their serum. Class and subclasses of antibodies 
to H. pylori are different. The IgA and IgG type antibodies are 
seen in chronic infections, and IgM be found in acute 
infections.6-7 Metabolic syndrome (MS) is a global epidemic 
and appears in common genetic and environmental media, and 
it is characterized by cardio metabolic risk factors, such as 
abdominal obesity, atherogenic dyslipidemia, glucose 
intolerance, and elevated blood pressure.8 MS is a 
heterogeneous disease that develops because of insulin 
resistance (IR), and in 2011, the National Cholesterol 
Education Program Adult Treatment Panel III (NCEP ATP III) 
specified the major components of MS as abdominal obesity, 
IR, elevated body pressure, and dyslipidemia.8 Given the 
prevalence of metabolic syndrome and disorders of the multiple 
Internal organs and tracts, including the immune system, 
serological diagnosis testing of H. pylori infection may be 
impaired.9 Considering the high prevalence of MS among 
individuals and high prevalence of H. pylori infection, this 
study was done with the aim of comparing the diagnostic 
accuracy of serological and histology tests for H. pylori in 
patients with dyspepsia and metabolic syndrome. 
Materials and Methods 
All patients referred to the Shahroud Imam Hossain 
Hospital Gastroenterology polyclinic with gastrointestinal 
problems were selected. Exclusion criteria included the 
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following: patients who received proton pump inhibitors, 
histamine type 2 (H2) receptor antagonists and H. pylori 
eradication therapy in the last month, pregnant women, patients 
who had been diagnosed with malignancy and patients who had 
undergone gastric surgery. Patients who were between18 -70 
years old, patients without psychiatric or systematic disease 
like diabetes, chronic kidney, and systematic infection were 
included in this study. A total of 175 patients were enrolled and 
approved by the Shahroud Imam Hossain Hospital. All eligible 
patients who provided written, informed consent were recruited 
for this study. Then, endoscopy division was used following 
local anesthesia of the pharynx, which was performed with 
procaine. Using the endoscope, six biopsy specimens were 
obtained from the large and small curvature, and anterior and 
posterior walls of the gastric antrum and corpus mucosa of all 
patients. The specimens were transferred to the pathology 
laboratory and fixed with 10% formalin. H. pylori were 
observed in the biopsy specimens by microscopic examination 
of the slides stained with hematoxylin and eosin. Slides were 
examined by two experienced pathologists. Also, 5 ml of 
venous blood was taken from each patient to measure IgG 
against H. pylori by ELISA (Biotech Trinity of Germany). 
Serology test results were analyzed according to the 
manufacturer recommendations. If the antibody titer equal or 
greater than 1.1 units, the test was positive, between 0.8 and 1 
unit was considered borderline (suspicious), and less than 0.7 
unit was negative. It should be noted that, for better results, 
only greater than or equal to 1.1 units antibody was considered 
positive, and negative results and borderline values were 
considered negative. 
Diagnostic criteria for metabolic syndrome (ATP III) 
include the following: abdominal obesity (waist circumference) 
for men >102 cm, and for women >88 cm; triglycerides, ≥150 
mg/dL; HDL cholesterol for men <50 mg/dL and for women 
<40 mg/dL; blood pressure ≥130/85; fasting glucose ≥110 
mg/dL.  
SPSS version 16 was used to analyze and tabulate the data. 
In this study, pathological tests were standard procedures, and 
the sensitivity, specificity, and positive and negative predictive 
value of serology tests (IgG) were calculated based on 
pathological tests. Receiver Operating Characteristic Curve 
(ROC curve) was used to estimate the cut-off point for 
seropositive tests. In ROC analysis, the accuracy of each test 
with the area under the curve (AUC) (from 0 to 100%) is 
expressed. Continuous variables were presented as mean and 
standard deviation, whereas frequency and percentage were 
used for the presentation of categorical variables. 
Results  
Of the 175 patients studied, 90 (51.4%) were male and 85 
(48.6%) were female. The mean patient age was 52.9±18.6 
years (rang 28–69 years). Body mass index was 25.7±5.6 
kg/m2, and the average amount of IgG against H. pylori in 
patients was 1.3±1.2 international units (range 0–2.5 
international units). Histology test results were positive for H. 
pylori in 149 patients (85.3%), while serologic testing for H. 
pylori was positive in 114 patients (65.1%). The age group of 
51–60 years were the most commonly serologically positive. 
Serological and histological tests results for separate age 
groups are shown in Table 1. In this table, to investigate the 
prevalence of pathology and serology at different ages, the age 
classification was used. The average duration of digestive 
problems was 19.3±15.7 months (range 4–35 months). For the 
serology testing of IgG, 114 patients (65.3%) were positive, 26 
patients (14.7%) were borderline (suspicious), and 35 (20%) 
were negative. Table 2 shows that 149 cases (85.3%) tested 
positive by histology. Considering the results of histology as 
the gold standard in comparison with the results of serology, 
the sensitivity, specificity, positive predictive value and 
negative predictive value of serological test was 66.4% (95% 
CI: 61.5%–71.0%), 42.3% (95% CI: 37.6%–46.4%), 86.8% 
(95% CI: 82.4%–91.5%), and 18.1% (95% CI: 15.5%–21.4%), 
respectively. The results are shown in Table 2. 
Table 2: Comparison of serology and histology in the diagnosis of 
Helicobacter pylori infection in metabolic syndrome patients 
Total Negative Histology (%) Positive Histology (%)  
114 15 99 Seropositive 
61 11 50 Seronegative 
175 26 149 Total 



















12(6.9) 8(7.1) 2(7.7) 2(5.7) 12(6.9) 9 (6.1) 3 (11.5) <40  
48(27.4) 30(26.3) 7(26.9) 11(31.4) 48(27.4) 41 (27.5) 7 (20) 40-50  
76(43.4) 54(47.4) 10(38.5) 12(34.3) 76(43.4) 65 (43.6) 11(42.3) 51-60  
39(22.3) 22(19.3) 7(26.9) 10(28.6) 39(22.3) 34(22.8) 5(14.3) 61-70  
175 (100) 114 (65.1) 26 (14.9) 35 (20) 175 (100) 149 (85.3) 26 (14.7) Total 
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Figure 1: Evaluate the diagnostic value of serologic testing for H. pylori in 
patients undergoing MS (ROC Curve) 
According to figure number one (curve ROC), cut-off 
point, was 1.3 unit, and area under the ROC curve (AUC) was 
78.3 percent (95% CI: 69.4%–87.1%).  
In other words, IgG values higher than 1.3, with a 
sensitivity of 90.7%, and specificity of 72.8%, were considered 
positive, and less than this level considered a negative test. The 
cut-off point performance test means that maximum at this 
point, the AUC  with 78.3%,   have the highest sensitivity and 
specificity. 
Discussion 
In this study, the sensitivity of the serological test based on 
biopsies from patients with metabolic syndrome was 66.4%, 
the specificity was 42.3%, the positive predictive value was 
86.8%, and the negative predictive value was 18.1%, 
respectively. In Salimi study, sensitivity, specificity, positive 
predictive values, and negative predictive values were similar 
to our study.8 Although the relationship between MS and H. 
pylori, which is one of the infectious agents that associated 
with MS, has not been completely explained, H. pylori 
infection impairs the balance of proinflammatory cytokines and 
CRP, angiotensinogen, free fatty acids, and leptin, and thus, 
reactive oxygen radicals begin to accumulate.9-12 Subclinical 
chronic inflammation occurs via impaired cytokine balance and 
stimulated macrophages. This leads to unresponsiveness to 
insulin in the peripheral tissue and subsequently to MS.13-14 In 
the study of Aslan in more than 150 MS patients, sensitivity 
and specificity of IgG were 78% and 76%, respectively. In the 
study of Gunji sensitivity and specificity were 73.7% and 
49.6%, respectively, and in the study of Al-Humayed, 
sensitivity was 77% and specificity was 37.3%, which are 
similar to our study.15-17 In the study of Islam and Longo-
Mbenza, sensitivity and specificity of IgG were 83% and 75%, 
respectively.18-19 In the Kucukazmanin study, the sensitivity 
and specificity of serologic tests were 67% and 93%, 
respectively.20 In this study, the positive predictive value was 
91.8%, and the negative predictive value was 26.9%, but the 
results of similar studies, such as the study of Sung, Hasler in 
India and Elizalde and Takashima in Japan, a significant 
difference was observed, probably because of trials, sample 
size, or population differences in these areas.21-24 The present 
study differs from some studies, such as research by Henry in 
Italy and Ando and Kanbay,25-27 in that these studies considered 
the urea breath test, stool antigen tests for H. pylori, and other 
comparisons. A study conducted by Kyriazanos showed that 
the combination of serology and histology have higher positive 
predictive values than either test alone.28 Although this study 
only determined the sensitivity and specificity of serologic tests 
for detection of H. pylori in patients with metabolic syndrome, 
a two-year-old study by Sam brook and Papa Michael showed 
that the accuracy of these tests in metabolic syndrome, in 
comparison to biopsy, are significantly lower than in non-MS 
patients.29-30 Unfortunately, despite numerous studies, 
conclusions cannot be made as few major studies have been 
conducted with sufficient sample size. Furthermore, there are 
limited studies in different races, and with non-identical 
specimens that have been designed and implemented. 
Therefore, small studies are often difficult due to uncontrolled 
confounding factors, which often occur due to the sample size. 
The limitations of this study were small sample size and 
high cost of laboratory kits, which was resolved with the 
financial support of Imam Hussein hospital officials. 
Finally, this study showed that the correlation between the 
results of serological tests of patients with and without MS do 
not exist, and therefore IgG serology testing is valuable since it 
is a sensitive and non-invasive diagnosis of H. pylori infection 
and is easy to implement at low cost. Furthermore, it can be 
used for epidemiological studies and screening. Also according 
to the findings of this study (Figure ROC), a cut point of 1.3 
can be used for serological diagnosis of H. pylori infection in 
MS patients. 
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